Biotech Stock Roundup: BMY, GSK, BIIB's Q2 Results, VTVT Down on Setback
https://www.zacks.com/stock/news/2314600/biotech-stock-roundup-bmy-gsk-biib-s-q2-results-vtvt-down-on-setback?cid=CS-ZC-FT-analyst_blog|stock_roundup-2314600
Aug 01, 2024 - Bristol Myers (BMY) and Biogen (BIIB) are in the spotlight following earnings results and regulatory updates, respectively.
0
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
https://www.zacks.com/stock/news/2312313/watch-these-5-biotech-stocks-for-q2-earnings-beat-or-miss?cid=CS-ZC-FT-analyst_blog|earnings_preview_esp-2312313
Jul 30, 2024 - Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
0
What Awaits Biogen (BIIB) in Q2 Earnings Post Leqembi Setback?
https://www.zacks.com/stock/news/2311049/what-awaits-biogen-biib-in-q2-earnings-post-leqembi-setback?cid=CS-ZC-FT-analyst_blog|earnings_preview-2311049
Jul 29, 2024 - Biogen's (BIIB) sales in the second quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been hurt by increased competition.
0
The Zacks Analyst Blog Highlights Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical
https://www.zacks.com/stock/news/2310051/the-zacks-analyst-blog-highlights-sage-therapeutics-biogen-agenus-and-biomarin-pharmaceutical?cid=CS-ZC-FT-press_releases-2310051
Jul 26, 2024 - Sage Therapeutics, Biogen Agenus and BioMarin Pharmaceutical are part of the Zacks top Analyst Blog.
0
SAGE Rides on Zurzuvae Sales, Pipeline Setbacks a Concern
https://www.zacks.com/stock/news/2305353/sage-rides-on-zurzuvae-sales-pipeline-setbacks-a-concern?cid=CS-ZC-FT-analyst_blog|zer_report_update-2305353
Jul 19, 2024 - Sage Therapeutics' (SAGE) Zurzuvae, approved for treating postpartum depression, holds an excellent commercial opportunity. The recent pipeline setbacks are, however, an overhang.
0
Ionis (IONS) Completes Enrolment for Rare Disease Drug Study
https://www.zacks.com/stock/news/2305396/ionis-ions-completes-enrolment-for-rare-disease-drug-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2305396
Jul 19, 2024 - Ionis' (IONS) late-stage study is evaluating zilganersen in a rare neurological disorder called Alexander disease. Top-line data from this study is expected by the end of the next year.
0
Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
https://www.zacks.com/stock/news/2302828/lexeo-lxeo-down-despite-upbeat-rare-disease-gene-therapy-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2302828
Jul 16, 2024 - Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.
0
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
https://www.zacks.com/stock/news/2296481/eli-lilly-lly-gets-fda-nod-for-alzheimer-s-drug-donanemab?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2296481
Jul 03, 2024 - Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
0
This Is Massive News for Eli Lilly Investors
https://www.fool.com/investing/2024/06/29/this-is-massive-news-for-eli-lilly-investors/?source=iedfolrf0000001
Jun 29, 2024 - A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate.
0
FDA Accepts Ionis' (IONS) NDA for Rare Disease Drug Olezarsen
https://www.zacks.com/stock/news/2293892/fda-accepts-ionis-ions-nda-for-rare-disease-drug-olezarsen?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2293892
Jun 26, 2024 - The FDA grants priority review to Ionis' (IONS) filing seeking approval for olezarsen to treat adults with familial chylomicronemia syndrome. A final decision is expected in December 2024.
0